Ownership and insider activity for Revolution Medicines, Inc. (RVMD): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers.
Price
| Price | $188.72 (closing price, October 28, 2026) |
| Market Cap | $40.4B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-29 | Sandler Alan B. | M-Exempt | 6,000 | $353K |
| 2026-09-29 | Sandler Alan B. | M-Exempt | 6,000 | $353K |
| 2026-09-29 | Sandler Alan B. | S-Sale | 2,200 | $442K |
| 2026-09-29 | Sandler Alan B. | S-Sale | 1,609 | $325K |
| 2026-09-29 | Sandler Alan B. | S-Sale | 1,000 | $203K |
| 2026-09-29 | Sandler Alan B. | S-Sale | 1,199 | $244K |
| 2026-09-29 | Sandler Alan B. | S-Sale | 301 | $62K |
| 2026-09-25 | Cislini Jeff | S-Sale | 765 | $159K |
| 2026-09-25 | Mancini Anthony | M-Exempt | 3,121 | $105K |
| 2026-09-25 | Mancini Anthony | M-Exempt | 3,121 | $105K |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.1M | $69.6M | $16.7M | $104.3M | $108.5M | $161.4M | $696.1M | $543.1M | $383.7M |
| Short-term Investments | 0 | 0 | $106.1M | $336.5M | $468.6M | $483.5M | $1.16B | $1.75B | $1.64B |
| Receivables | 0 | $7.3M | $8.7M | $6.4M | $5.9M | $4.7M | $1.3M | 0 | 0 |
| Inventory | 0 | $6.6M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $9.4M | $85.4M | $134.0M | $454.1M | $589.8M | $660.2M | $1.88B | $2.33B | $2.08B |
| Property, Plant & Equipment | $5.3M | $6.9M | $7.1M | $36.3M | $71.2M | $73.7M | $100.0M | $141.8M | $165.3M |
| Goodwill | 0 | $14.6M | $14.6M | $14.6M | $14.6M | $14.6M | $14.6M | $14.6M | $14.6M |
| Intangible Assets | 0 | $63.1M | $62.0M | $60.9M | $59.9M | $58.8M | $57.7M | $56.7M | $55.8M |
| Total Assets | $15.1M | $170.6M | $220.5M | $567.4M | $738.0M | $811.9M | $2.06B | $2.56B | $2.35B |
| Accounts Payable | $3.4M | $5.2M | $11.4M | $12.6M | $14.1M | $21.3M | $61.8M | $54.4M | $64.6M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $7.6M | $30.6M | $43.1M | $47.2M | $60.4M | $62.0M | $143.9M | $163.9M | $290.4M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $142.2M |
| Total Liabilities | $10.5M | $73.9M | $68.0M | $92.7M | $135.4M | $126.7M | $235.5M | $293.1M | $723.2M |
| Retained Earnings | -$67.9M | -$109.7M | -$157.4M | -$265.5M | -$452.6M | -$701.3M | -$1.14B | -$1.74B | -$2.87B |
| Total Equity | $4.5M | $96.7M | $152.5M | $474.7M | $602.6M | $685.2M | $1.83B | $2.27B | $1.63B |
| Total Debt | 0 | $147,000 | 0 | $32.7M | $66.6M | $64.2M | $87.9M | $135.8M | $158.7M |
| Net Debt | -$9.1M | -$69.4M | -$122.8M | -$408.1M | -$510.4M | -$580.7M | -$1.77B | -$2.15B | -$1.87B |
| Working Capital | $1.8M | $54.9M | $90.9M | $406.9M | $529.4M | $598.2M | $1.74B | $2.16B | $1.78B |
Financial Health
| Debt / Equity | 0.25 |
| Current Ratio | 11.38 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 10.11 |
Profitability
| Return on Equity | -96.44% |
| Return on Invested Capital | -40.82% |
| Return on Assets | -40.90% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ERAS · ELVN · IDYA · RLAY · TNGX · NRIX
Explore sector: Healthcare · Biotechnology
More sections of RVMD: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks